Best Immunology Companies in England, United Kingdom
The 58 best Immunology companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immunocore.
Ranked: Best Immunology companies in England
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunocore Developer of bispecific T cell receptor therapies for human diseases | $525M | 47 mo ago | 293 293 → 604 (+106%) | Nicholas Cross Co-Founder | Public | 776 patents Patents concentrated in chemistry & materials | 3 job openings · 1 launch |
| 2 | Apollo Therapeutics Developer of therapeutic programs based on biological and medical research | $372M | 34 mo ago | 11 | Richard Mason CEO | Series C | — | — |
| 3 | Quell Developer of engineered regulatory T cell therapies for immune diseases | $344M | 42 mo ago | 18 | Giovanna Lombardi Co-Founder | Series B | — | 1 partnership |
| 4 | Autolus Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases | $181M | 29 mo ago | 51 | Martin Pule Founder | Public | 648 patents Patents concentrated in chemistry & materials | 1 award |
| 5 | OMass Therapeutics Developer of therapeutics for immunological and orphan diseases | $166M | 37 mo ago | 36 36 → 78 (+117%) | Carol Robinson Co-Founder | Series B | 16 patents Small‑molecule modulators of MC2R, GPR65, and SMO receptors for endocrine and oncology therapies. | 1 job opening |
| 6 | MiroBio Developer of therapeutics for auto-immune diseases | $132M | 48 mo ago | 29 | Simon Davis Co-Founder | Acquired | 69 patents Therapeutic antibodies targeting BTLA and CD200R immune checkpoint proteins. | — |
| 7 | Zura Bio Developer of therapeutics for immunological diseases | $128M | 26 mo ago | 1 | Someit Sidhu CEO | Public | — | — |
| 8 | NodThera Developer of therapeutics for treating inflammatory and neuroinflammatory diseases | $95M | 73 mo ago | 19 19 → 27 (+42%) | Alan Watt CEO | Series B | 140 patents Synthesis of heterocyclic carbamate/urea compounds for inflammasome‑targeted drugs | — |
| 9 | Allergy Therapeutics Developer of treatments for allergy and immune related disorders | $94M | 95 mo ago | 601 601 → 380 (-37%) | — | Public | 45 patents Allergen-specific immunotherapy vaccines for food allergy treatment | — |
| 10 | Oxagen Developer of drugs for inflammatory and respiratory diseases | $86M | 199 mo ago | 3 | Richard Edwards Managing Director | Deadpooled | 153 patents CRTH2 antagonist small‑molecule pharmaceuticals and related solid‑form formulations | — |
| 11 | Microbiotica Developer of live bacterial therapeutics and biomarkers for multiple diseases | $83M | 52 mo ago | 42 42 → 55 (+31%) | Gordon Dougan Co-Founder | Series B | 30 patents Engineered therapeutic bacterial formulations for microbiome-based disease treatment | 1 award |
| 12 | Sitryx Biotechnology company focused on immunometabolism, developing therapies | $69M | 36 mo ago | 17 | Paul-Peter Tak Co-Founder & Director | Series B | — | — |
| 13 | ImmuPharma Company developing Lupuzor a potential treatment for Lupus with US FDA's fast track designation | $62M | 54 mo ago | 14 | Dimitri Dimitriou Co-Founder & CEO | Public | — | — |
| 14 | Pathios Developer of small molecule based therapeutics for the treatment of cancer | $58M | 16 mo ago | 9 | Kirsty McCarthy Co-Founder | Acquired | — | — |
| 15 | Immune Regulation Developer of smal molecule based therapeutics for inflammatory and respiratory diseases | $52M | 69 mo ago | 9 | Richard Nagle CEO | Series B | 23 patents Immunomodulatory therapeutic proteins and chaperonin-derived peptides for inflammation and TB | — |
| 16 | Mestag Therapeutics Developer of therapeutics for the treatment of cancer and inflammatory diseases 35Talent top 23%Funding top 28%Moat top 39%Tech bottom 46% All 6 signals ▾Talenttop 23% Fundingtop 28% Moattop 39% Techbottom 46% Globalbottom 37% Marketbottom 26% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated Funding: Raised $45.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $45M | 3 mo ago | 8 | David Tuveson Co-Founder | Series A | — | — |
| 17 | C4X Discovery Developer of optimized drug discovery and design services | $43M | 30 mo ago | 46 | — | Public | 130 patents Small‑molecule inhibitors of MALT1, NRF2 agonists, and integrin blockers for immuno‑inflammatory therapy | — |
| 18 | Nucleome Therapeutics Developer of nucleome therapeutics for multiple diseases | $42M | 44 mo ago | 14 | Jim Hughes Co-Founder | Series A | — | 1 job opening · 1 award |
| 19 | Trimtech Therapeutics They develop treatments for CNS and inflammatory disorders | $31M | 16 mo ago | — | Leo James Co-Founder | Seed | — | 1 award |
| 20 | PredictImmune Developer of tools for diagnosing immune-mediated inflammatory diseases | $18M | 83 mo ago | 15 | — | Series B | — | — |
| 21 | Xap Therapeutics Developer of cell therapies to treat cancer and autoimmune diseases | $17M | 52 mo ago | 12 | Shaun Foy Co-Founder | Seed | — | — |
| 22 | Midatech Provider of novel drug delivery technologies for the treatment of diseases | $16M | 41 mo ago | 40 40 → 24 (-40%) | — | Public | 204 patents Patents concentrated in health & consumer products | 1 job opening · 1 expansion |
| 23 | Maxion Therapeutics Developer of antibody-based drugs to treat multiple diseases | $16M | 15 mo ago | 4 | Aneesh Vellatt Co-Founder & CSO | Series A | — | 1 job opening |
| 24 | YorkTest UK-based, commerialized At-Home consumer diagnostics company developing food allergy and other allergy test… | $12M | 47 mo ago | 38 38 → 55 (+45%) | — | Acquired | — | 1 launch |
| 25 | Pangea Botanica Developing and discovering nature-inspired therapeutics | $12M | 38 mo ago | 8 | Julia Wilde Co-Founder | Seed | 2 patents Accelerated hardware implementations for high‑speed cosine arithmetic operations | — |
| 26 | Sareum Developer of small molecule therapeutics for cancer and autoimmune diseases | $11M | 35 mo ago | 6 | — | Public | 92 patents Small-molecule TYK2 kinase inhibitors for treating inflammatory and autoimmune diseases | — |
| 27 | CMP Therapeutics Developed treatment for allergy and infectious diseases in the form of intranasal devices or functional foods | $9M | 191 mo ago | 1 | — | Deadpooled | 22 patents Chitin-based microparticle formulations for nutraceuticals and medical therapeutics | — |
| 28 | Epsilon 3 Bio Developer of peptides and small molecules that stimulate autophagy | $9M | 72 mo ago | 1 | David Grainger Co-Founder & CEO | Series A | — | — |
| 29 | DJS Antibodies Developer of antibody therapeutics for inflammatory conditions | $8M | 29 mo ago | 16 | Robert Michael CEO | Acquired | 12 patents Therapeutic antibody polypeptide design and production technologies | — |
| 30 | Scarlet Therapeutics Developer of cell-based therapeutics to treat a wide range of diseases 14Talent top 28%Funding bottom 47%Global bottom 37%Market bottom 18% All 4 signals ▾Talenttop 28% Fundingbottom 47% Globalbottom 37% Marketbottom 18% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $7.1M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 14/100 | $7M | 2 mo ago | 3 | Jan Frayne Co-Founder & CTO | Series A | — | 1 job opening |
| 31 | Ignota Labs AI-driven toxicity prediction tools for early-stage drug discovery scientists | $7M | 16 mo ago | 9 | Layla Hosseini-Gerami Co-Founder | Seed | — | 2 partnerships · 1 award |
| 32 | Istesso Immunometabolism based drugs for autoimmune diseases | $7M | 91 mo ago | 5 | Lisa Patel Co-Founder & CEO | Series A | 21 patents Combination therapies targeting NF‑κB, TNF, JAK/IL‑6 pathways for inflammatory disease treatment | — |
| 33 | Orca Pharmaceuticals Develops oral drugs for the treatment of chronic inflammatory diseases | $4M | 142 mo ago | 2 | Michael Hunter Founder | Series A | 9 patents Small‑molecule RORγt inhibitors for autoimmune and inflammatory disease therapy | — |
| 34 | Microtest Diagnostics Automated allergy testing | $2M | 138 mo ago | 6 | Kjell Kristensen Group Managing Director | Series A | — | — |
| 35 | Apini Therapeutics Developer of small molecule therapeutics for the treatment of inflammatory diseases | $2M | 13 mo ago | — | Sam Butterworth Founder & CSO & Director | Seed | — | — |
| 36 | Ducentis BioTheapeutics Preclinical stage company developing therapeutics for inflammatory and auto-immune diseases | $2M | 85 mo ago | 6 | — | Acqui-Hired | — | — |
| 37 | NALIA Systems Customisable multiplexed Immunodiagnostic biomarker panels | $1M | 55 mo ago | 5 | — | Deadpooled | — | — |
| 38 | Bastion Therapeutics Developer of cell therapy for inflammatory disorders and autoimmune diseases | $1M | 28 mo ago | — | Nia Emami Co-Founder & CSO | Seed | — | — |
| 39 | Camallergy Provider of peanut protein oral immunotherapy | $1M | 64 mo ago | 11 | Sherden Timmins Co-Founder | Seed | — | — |
| 40 | Eleusis Developer of immunomodulatory and neuroprotective medicines | $495K | 52 mo ago | 1 | Charles Nichols Co-Founder | Acquired | — | — |
Top 12 Immunology companies in England
#1
Series A · Cambridge, England · founded 2020 · 8 employees$45Mraised▾
Developer of therapeutics for the treatment of cancer and inflammatory diseases. The company has developed therapeutics that interrupt pathological fibroblast-driven immune signaling and influence innate and adaptive immune responses.
- Mar 2026Series A$40M
- Aug 2024Grant (prize money)$2M
- Aug 2021Seed$34M
- Apr 2021Seed$11M
#2
Series A · Bristol, England · founded 2022 · 3 employees$7.1Mraised▾
Developer of cell-based therapeutics to treat a wide range of diseases. The company is focused on developing a proprietary platform to generate novel red blood cell-based therapeutics to potentially treat a wide range of diseases including metabolic diseases, autoimmune diseases, infectious diseases and cancer.
- May 2026Series A$3.8M
- Nov 2024Seed$959.8K
- May 2023Seed—
- Aug 2022Seed$2.4M
#3
Acquired · Oxford, England · founded 2017 · 9 employees$58Mraised▾
Developer of small molecule based therapeutics for the treatment of cancer. It is an oncology and immunology company that targets the acid-sensing GPCR, GPR65, as a unique and genetically-validated immune cell receptor with the potential to revolutionise oncology treatment across multiple solid tumor types.
- Feb 2025Series B$19M
- Feb 2024Series B$25M
- Jan 2023Series B$8.6M
- Oct 2021Series B$17.8M
#4
Seed · Cambridge, England · founded 2023$31Mraised▾
They develop treatments for CNS and inflammatory disorders. The company creates highly specific degraders that selectively target and remove toxic proteins. This approach is based on research into TRIM21, a ubiquitin ligase, to treat protein aggregation disorders. They aim to provide therapeutic benefits for intractable CNS and inflammatory diseases.
- Mar 2025Seed$31M
#5
Series A · Cambridge, England · founded 2020 · 4 employees$16Mraised▾
Developer of antibody-based drugs to treat multiple diseases. The company leverages a proprietary KnotBody technology that combines the power of Knottin evolution in targeting ion channels and GPCRs with state-of-the-art antibody engineering techniques to address autoimmunity, chronic pain, and cardiovascular diseases.
- Mar 2025Series A$72M
- Apr 2023Grant (prize money)$2.5M
- Feb 2023Series A$16M
#6
Public · London, England · founded 2015 · 51 employees$181.4Mraised▾
Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases. It leverages advanced immune cell engineering, chimeric antigen receptor (CAR) technology, and proprietary T cell programming platforms to create precise, controlled, and highly active therapeutic products designed to improve patient outcomes. Its technology platform combines innovative cell programming capabilities with proprietary viral vector systems and semi-automated manufacturing processes to engineer patient-derived T cells capable of recognizing and eliminating disease-causing cells.
- Feb 2024Post IPO$200M
- Nov 2021Post IPO—
- Sep 2017Series C$80M
- Mar 2016Series B$56M
#7
Series C · Cambridge, England · founded 2020 · 11 employees$371.5Mraised▾
Developer of therapeutic programs based on biological and medical research. The company's product pipeline include APL-9796: A first-in-class anti-ZIP12 monoclonal antibody for pulmonary hypertension, APL-045 and APL-10456, targeting neoplasms, immune disorders, and metabolic conditions via small molecules and antibodies.
- Sep 2023Series C$226.5M
- Jun 2021Series C$145M
#8
Public · Altrincham, England · founded 2022 · 1 employees$128.4Mraised▾
Developer of therapeutics for immunological diseases. It offers a lead candidate ZB-168, an anti-IL7Rα monoclonal antibody for immune disorders that target immune pathways in IL7 and TSLP.
- Apr 2024Post IPO$112.5M
- May 2023Post IPO$15.9M
#9
Seed · London, England · founded 2021 · 9 employees$6.9Mraised▾
Ignota Labs is a technology startup in the pharmaceutical sector that provides AI-driven toxicity prediction tools for early-stage drug discovery scientists. Their suite of tools, TOXSCAPE, helps scientists identify and understand safety issues during the drug discovery process, reducing expensive setbacks and delays.
- Feb 2025Seed$6.9M
#10
Public · Abingdon, England · founded 2008 · 293 employees$525Mraised▾
Developer of bispecific T cell receptor therapies for human diseases. These biological medicines utilize modular technology to modulate immune system activity. The therapies target diseased cells to facilitate destruction or reduce immune responses in patients with cancer, infectious diseases, and autoimmune conditions. The research and development process focuses on creating treatments that interact with the human leukocyte antigen system to address unmet medical needs.
- Jul 2022Post IPO$140M
- Feb 2021Post IPO$15M
- Jan 2021Series C$75M
- Jan 2021Conventional Debt$100M
#11
Series B · London, England · founded 2019 · 18 employees$344.2Mraised▾
Developer of engineered regulatory T cell therapies for immune diseases. This clinical-stage organization focuses on modifying a patient's own regulatory T cells to restore immune balance. These therapies aim to address conditions involving autoimmunity, chronic inflammation, and organ transplant rejection by dampening immune responses and preventing tissue damage. The approach utilizes cellular engineering to regulate immune activity and manage severe inflammatory disorders.
- Jan 2023Series B$24.1M
- Mar 2022Series B$57.9M
- Nov 2021Series B$156M
- Dec 2020Series A$34.9M
#12
Seed · Huntingdon, England · founded 2021$2.4Mraised▾
Developer of small molecule therapeutics for the treatment of inflammatory diseases. The company has developed a series of small molecule compounds specifically targeting the pro-inflammatory activity of eNAMPT. It is also, conducting preclinical studies in diabetic, cardiovascular, and psoriasis models, demonstrating the broad potential applications of their compounds.
- Jun 2025Seed$2.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What England researches in immunology
University of New England, NHS England, and New England Biolabs lead England's predominantly recent, cautiously optimistic immunology research, focusing on cancer immunotherapy, CAR-T therapy, and inflammasome-related immune disorders.
- University of New England4
- NHS England2
- New England Biolabs2
- Public Health England1
- New England Cancer Specialists1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.